Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1 Immune Checkpoint Inhibitor (ICI) in Metastatic Clear Cell (mcc) Renal Cell Carcinoma (RCC): Result...

Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1 Immune Checkpoint Inhibitor (ICI) in Metastatic Clear Cell (mcc) Renal Cell Carcinoma (RCC): Result...

kidneycancer

3 weeks
32 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Chung-Han Lee1, Amishi Y. Shah2, Vicky Makker1, Matthew Taylor3, David Shaffer4, James J. Hsieh5, Allen L. Cohn6, Chris DiSimone7, Alvaro Pinto Marin8, Drew Rasco9, Sara Gunnestad Ribe10, Donald A. Richards11, Daniel E. Stepan*, Corina E. Dutcus12, Jane Wu12, Emmett V. Schmidt13, Rodolfo Perini13, Robert Motzer1 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2MD Anderson Cancer Center, University of Texas, Houston, TX, USA; 3Oregon Health and Science University; Portland, OR, USA; 4New York Oncology Hematology, Albany, NY, USA; 5Washington University School of Medicine, St. Louis, MO, USA; 6Rocky Mountain Cancer Center, Denver, CO, USA; 7Arizona Oncology Associates, Tucson, AZ, USA; 8Hospital Universitario La Paz, Madrid, Spain; 9South Texas Accelerated Research Therapeutics, San Antonio, TX, USA; 10Sorlandet Hospital, Kristiansand, Norway; 11Texas Oncology, US Oncology Research, Tyler, TX, USA; 12Eisai Inc., Woodcliff Lake, NJ, USA; 13Merck & Co. Inc., Kenilworth, NJ, USA. *Formerly of Eisai Inc. 18th International Kidney Cancer Symposium 2019, Miami, FL.

__________

Interview here: https://www.oncologytube.com/video/phase-2-study-of-lenvatinib-plus-pembrolizumab-for-disease-progression-after-pd-1-pd-l1

Up Next Autoplay
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Update on Phase I REGN1979 #ASH19 #ASH @RutgersCancer
Category: Non-Hodgkin Lymphoma
2 Views
ash 1 hour
REGN5458 @RutgersCancer #ASH #ASH19
REGN5458 @RutgersCancer #ASH #ASH19
Category: Multiple Myeloma
0 Views
ash 2 hours
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Phase 3 ICARIA-MM trial of isatuximab #ASH19 #ASH @sanofi
Category: Multiple Myeloma
0 Views
ash 9 hours
CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH
CARTITUDE-1: How is This Different from Others? @MountSinaiNYC @DMadduri #ASH19 #ASH
Category: Multiple Myeloma
2 Views
ash 10 hours
CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528 @MountSinaiNYC @DMadduri
CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528 @MountSinaiNYC @DMadduri
Category: Multiple Myeloma
2 Views
ash 10 hours
CAR-T Cell Imaging Markers: How This Affects Clinicians @PennMedicine
CAR-T Cell Imaging Markers: How This Affects Clinicians @PennMedicine
Category: Immunotherapy
0 Views
Cancer-News 11 hours
How Sensitive is the Technology? @PennMedicine @sellmyerlab
How Sensitive is the Technology? @PennMedicine @sellmyerlab
Category: Immunotherapy
0 Views
Cancer-News 11 hours
CAR-T Cells With Imaging Markers @PennMedicine sellmyerlab @sellmyerlab
CAR-T Cells With Imaging Markers @PennMedicine sellmyerlab @sellmyerlab
Category: Immunotherapy
0 Views
Cancer-News 11 hours
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Category: Chronic Myelogenous Leukemia
4 Views
iCMLf 1 day
Perspectives on the Future of CML
Perspectives on the Future of CML
Category: Chronic Myelogenous Leukemia
2 Views
iCMLf 1 day